The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 1002).
Jin Matsuyama
No relevant relationships to disclose
Kazumasa Fujitani
No relevant relationships to disclose
Shigeyuki Tamura
No relevant relationships to disclose
Yutaka Kimura
No relevant relationships to disclose
Hiroshi Imamura
No relevant relationships to disclose
Junya Fujita
No relevant relationships to disclose
Shohei Iijima
No relevant relationships to disclose
Shugo Ueda
No relevant relationships to disclose
Toshio Shimokawa
No relevant relationships to disclose
Yukinori Kurokawa
No relevant relationships to disclose
Taroh Satoh
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose